Clomiphene citrate mild stimulation improved follicular development outcomes in PCOS women with high luteinizing hormone and poor ovarian response: A case report.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
entrez:
25
10
2022
pubmed:
26
10
2022
medline:
27
10
2022
Statut:
ppublish
Résumé
Polycystic ovary syndrome (PCOS) is a main cause of anovulatory infertility in women of reproductive age. About 30% to 50% of patients with PCOS has high serum basal luteinizing hormone (LH) levels, and almost 5% of PCOS women with high LH have poor ovarian response (POR). We reported a case of a PCOS woman with high basal LH levels who canceled due to POR during two consecutive controlled ovarian stimulation treatments, which was considered to be related to the suppression of LH levels during downregulation. Clomiphene citrate (CC) combined with human menopausal urinary gonadotropin (HMG) mild regimen did not affect LH levels and obtained good follicular development, providing a new treatment insight for patients with PCOS combined with POR. A 28-year-old PCOS woman with high basal LH levels, underwent IVF assisted pregnancy treatment in our hospital, whom canceled due to POR during two traditional controlled ovulation induction program. Follicular development was finally achieved with CC milder protocol. This patient with the diagnosis of PCOS was undergone IVF assisted pregnancy treatment in our hospital. CC protocol supports the development of follicular. CC protocol resulted in better follicular development and high-quality embryos due to the continuous maintenance of an elevated LH levels. PCOS women with poor ovarian response required relatively higher LH to maintain the normal development of follicles.
Identifiants
pubmed: 36281179
doi: 10.1097/MD.0000000000031323
pii: 00005792-202210210-00102
pmc: PMC9592273
doi:
Substances chimiques
Clomiphene
1HRS458QU2
Luteinizing Hormone
9002-67-9
Fertility Agents, Female
0
Menotropins
61489-71-2
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31323Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Chang S, Dunaif A. Diagnosis of polycystic ovary syndrome: which criteria to use and when? Endocrinol Metab Clin North Am. 2021;50:11–23.
Khattak M, Sultana N, Usman R, et al. Luteinizing hormone to follicle stimulating hormone ratio in patients with polycystic ovary syndrome. J Ayub Med Coll Abbottabad. 2020;32:255–8.
Coyle C, Campbell RE. Pathological pulses in PCOS. Mol Cell Endocrinol. 2019;498:110561.
Verpoest WM, Cahill DJ, Harlow CR, et al. Relationship between midcycle luteinizing hormone surge quality and oocyte fertilization. Fertil Steril. 2000;73:75–7.
Ye H, Tian H, He W, et al. Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes and suboptimal pregnancy outcomes compared with the standard progestin-primed ovarian stimulation in infertile women with polycystic ovarian syndrome. Reprod Biol Endocrinol. 2018;16:53.
Siristatidis CS, Gibreel A, Basios G, et al. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev. 2015;9:CD006919.
Ferraretti AP, La Marca A, Fauser BC, et al. ESHRE working group on poor ovarian response definition. ESHRE consensus on the definition of “poor response” to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616–24.
Gardner DK, Weissman A, Howles CM, et al. Textbook of reproductive techniques: laboratory perspectives. 4th ed. [M]. London: Informa Health Press. 2012. 240–253
Jiang M, Wang C, Fei X, et al. Pregnancy confirmed after controlled ovarian stimulation for infertility: a case report. Medicine (Baltim). 2021;100:e27140.
Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28:2562–9.
Raju GA, Chavan R, Deenadayal M, et al. Luteinizing hormone and follicle stimulating hormone synergy: a review of role in controlled ovarian hyper-stimulation. J Hum Reprod Sci. 2013;6:227–34.
Wong PC, Qiao J, Ho C, et al. Asia Pacific fertility advisory group. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod Biomed Online. 2011;23:81–90.
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–77.
Alviggi C, Andersen CY, Buehler K, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105:1452–3.